Shanghai Fosun Pharmaceutical (Group) Co., Ltd.SSE: 600196

Announcement on New Drug Indication Obtaining Registration Approval for a Holding Subsidiary

· Issued by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary has received registration approval for a new indication of a drug. The approved indication is for treating children and adolescents with a specific rare disease after systemic therapy. The filing includes details about the drug's registration information and its market situation. The company highlights the potential impact on market competitiveness and warns of uncertainties in sales post-approval.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on New Drug Indication Obtaining Registration Approval for a Holding Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on 6ix

Earlier from Shanghai Fosun Pharmaceutical (Group)

Later from Shanghai Fosun Pharmaceutical (Group)

All Shanghai Fosun Pharmaceutical (Group) news releases